PubMed Health⌕ Search

Biomedical subjects

C M Oliner

Publications and source records attributed to C M Oliner.

3 recordsLinked to original sources
PubMed1992

The effect of food matrix on carbohydrate utilization during moderate exercise.

The effect of food matrix on carbohydrate utilization during moderate exercise. Med. Sci. Sports Exerc., Vol. 24, No. 3, pp. 320-326, 1992. To determine the effect of food type and form on the rate of assimilation and utilization of a meal given before exercise, five physically active adult males walked for 4 h on a 10% uphill graded treadmill at 40% VO2max. After a 12-h fast, and 30 min before exercise, subjects ingested 70 g of liquid glucose (G), a refined "hot cereal" (R), a refined "hot cereal" with water-soluble fiber (R/F), an oat bar (O), or placebo (P). Meals R/F, R, and O had significantly lower (P less than 0.05) peak plasma glucose responses than meal G (0.8, 0.9, 1.0, and 2.4 mmol.l-1, respectively). Meals R, O, and R/F had significantly lower (P less than 0.01) peak insulin responses than meal G (135, 150, 190, and 340 pmol.l-1, respectively). All meals except P contained an extrinsic tracer of 200 mg UL-13C-glucose. Mean (+/- SD) total recovery of the administered dose of 13C for all meals was 81 +/- 2%. Both O (34 +/- 4% dose.h-1) and R/F (30 +/- 3% dose.h-1) had significantly lower peak recoveries than did meal G (41 +/- 5% dose.h-1). Meal R/F had a significantly lower (P less than 0.05) rate of exogenous glucose oxidation than meal G during the first hour of exercise. These data suggest that meal R/F slows the rate of assimilation and utilization of exogenous glucose, but does not alter the cumulative 4-h utilization.

Adult↗
PubMed1990

Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension.

The renal and hemodynamic effects of intravenously administered fenoldopam mesylate, a novel dopamine-1 receptor agonist, were compared with those of sodium nitroprusside in 28 patients (18 male; 26 black, two white; average age, 49 +/- 3 years) with an average blood pressure of 219/137 mm Hg, most of whom presented with acute target organ damage. Fenoldopam and nitroprusside lowered blood pressure safely to an average pressure of 176/105 mm Hg; highly significant dose-response relations were found for the 13 patients receiving fenoldopam and the 15 receiving nitroprusside. Volume and sodium, potassium, and creatinine concentrations were measured in freely voided urine specimens both before and during intravenous therapy. In the fenoldopam-treated patients, there were significant increases in urinary flow (92 +/- 21 to 168 +/- 37 ml/hr, p less than 0.003), sodium excretion (227 +/- 73 to 335 +/- 90 mu eq/min, p less than 0.001), and creatinine clearance (70 +/- 11 to 93 +/- 13 ml/hr, p less than 0.003). In the nitroprusside-treated group, however, all these parameters decreased, but not significantly. For direct comparison of the two agents, the increments in urinary flow rate (+76 +/- 20 vs. -16 +/- 15 ml/hr, fenoldopam vs. nitroprusside), sodium excretion (+109 +/- 28 vs. -39 +/- 28 mu eq/min), and creatinine clearance (+23 +/- 6 vs. -11 +/- 7 ml/min) were significantly greater (p less than 0.001 for each) in the fenoldopam-treated group. Significant differences were also obtained when these parameters were calculated as percentage increase over baseline. Fenoldopam and nitroprusside are effective therapies for severe, accelerated, or malignant hypertension, but fenoldopam had additional salutary renal effects in these patients.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗